# South Korea Personalized Medicine Market > South Korea Personalized Medicine Market Research Report By Product Outlook (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness), By Application Outlook (Oncology, CNS, Immunology, Respiratory, Others) and By End-User Outlook (Hospitals, Diagnostic Centers, Research Academic Institutes, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.42% - **2024:** $ 14.92 Billion - **2025:** $ 15.88 Billion - **2035:** $ 29.57 Billion - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck & Co. (US), Amgen (US) **Report ID:** MRFR/HC/43629-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-personalized-medicine-market-45309 --- ## Market Summary ## **South Korea Personalized Medicine Market Overview** As per MRFR analysis, the South Korea Personalized Medicine Market Size was estimated at 13.91 (USD Billion) in 2023.The South Korea Personalized Medicine Market is expected to grow from 15.5(USD Billion) in 2024 to 37.7 (USD Billion) by 2035. The South Korea Personalized Medicine Market CAGR (growth rate) is expected to be around 8.416% during the forecast period (2025-2035). **Key South Korea Personalized Medicine Market Trends Highlighted** Numerous important market factors, such as developments in genetics and biotechnology, are causing notable changes in the South Korean personalized medicine market. Research and development is encouraged by the government's efforts to improve healthcare facilities, such as those carried out by the Ministry of Health and Welfare. As healthcare providers transition from conventional treatments to targeted medicines, increased investments in the biopharmaceutical industry have also contributed to the expansion of personalized medicine. Partnerships between biotech firms and academic institutions are opening the door to novel, individualized treatment solutions catered to the requirements of each patient. Opportunities-wise, the emergence of big data analytics and artificial intelligence (AI) opens up new growth paths for the South Korean market. Because of the nation's strong IT infrastructure, combining AI with customized medicine can improve patient outcomes and drug discovery procedures. Additionally, there will probably be a greater need for individualized treatment programs as the population ages and chronic illnesses become more common. Additionally, a favorable environment for the growth of personalized medicine solutions is being created by patients' and healthcare professionals' increased knowledge of the advantages of customized therapies. Integrating genetic testing into standard medical procedures is becoming more and more important, according to recent trends in the South Korean personalized medicine market. This change aids in both tracking the efficacy of treatments and early disease detection. Furthermore, more South Koreans are looking for individualized medical care as preventive healthcare gains greater attention. This trend is also being aided by the growth of telemedicine and digital health technologies, which are opening up individualized treatments to a wider audience. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Personalized Medicine Market Drivers** **Increasing Prevalence of Chronic Diseases** The rising prevalence of chronic diseases, including cancer, cardiovascular ailments, and diabetes in South Korea is a significant driver for the South Korea Personalized Medicine Market. According to the Korean National Health Insurance Service, chronic diseases account for approximately 60% of all deaths in the country, with cancer being the leading cause. The incidence rate of cancer in South Korea has steadily increased, with reports indicating a 20% rise in cancer cases over the past decade. This surge necessitates personalized treatment approaches tailored to individual genetic profiles, thereby boosting demand in the personalized medicine sector. Additionally, organizations such as the Korean Cancer Association are invested in promoting research and treatment strategies that focus on personalized medicine, further enhancing the market growth potential within this region. **Government Support and Initiatives** The South Korean government has been actively promoting personalized medicine through various initiatives, significantly impacting the South Korea Personalized Medicine Market. In 2020, the government announced its commitment to foster innovative medical technologies, allocating substantial funds to support research and development in the personalized medicine field. The Ministry of Health and Welfare has also prioritized developing a national biobank to enhance genetic research capabilities. Such supportive measures underscore government involvement, which is crucial for the growth of personalized medicine in South Korea, essentially creating a favorable environment for organizations like the Korea Health Industry Development Institute to contribute to innovations in this sector. **Advancements in Genomic Technologies** The rapid advancement of genomic technologies, particularly in the fields of genetic sequencing and bioinformatics, is driving the growth of the South Korea Personalized Medicine Market. In the past few years, the cost of whole-genome sequencing has decreased significantly, enabling more widespread access to genetic testing. For example, the Korean Genome Project was launched to sequence and analyze the genomes of Korean individuals, thus enhancing the understanding of genetic dispositions to various diseases. As a result, more healthcare providers are adopting genomic testing as a prerequisite for personalized treatments, making it an essential driver for market growth in the region. **Growing Awareness and Demand for Tailored Treatments** There is a notable increase in awareness and demand for tailored medical treatments among patients in South Korea, contributing to the development of the South Korea Personalized Medicine Market. Educational campaigns led by healthcare providers and patient advocacy groups emphasize the benefits of personalized medicine, leading to a higher demand for individualized treatment plans. According to recent surveys conducted by the Korea Institute of Healthcare and Social Affairs, over 75% of surveyed patients expressed a keen interest in understanding how their unique genetic profiles could influence treatment outcomes. This growing patient-centric approach aligns with trends observed in global healthcare, propelling growth in the personalized medicine sector in South Korea. **South Korea Personalized Medicine Market Segment Insights** **Personalized Medicine Market Product Outlook Insights** The South Korea Personalized Medicine Market is experiencing significant growth, fueled by advancements in technology, an increase in chronic diseases, and a rising demand for tailored healthcare solutions. Within the Product Outlook segment, several key categories have emerged, including Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition and Wellness. Personalized Medicine Diagnostics utilizes genomic sequencing and biomarkers to develop personalized treatment plans. This approach ensures accuracy in diagnosis and treatment, thus optimizing therapeutic outcomes. Personalized Medicine Therapeutics focuses on the development of therapies that are tailored to individual patient profiles, which not only enhances efficacy but also minimizes adverse effects, making it a pivotal area in the market that sees substantial investment and innovation. The significance of Personalized Medical Care cannot be understated, as it emphasizes patient-centric approaches, integrating data analytics to efficiently manage treatment methodologies and patient information. This market segment aligns with South Korea's healthcare goals of enhancing patient experience and treatment effectiveness through personalized attention. Furthermore, Personalized Nutrition and Wellness is gaining traction, especially as the population becomes more health-conscious and seeks customized dietary solutions that cater to individual health conditions and genetic profiles. This aspect of the market addresses the growing trend of preventive healthcare, wherein nutrition plays a vital role in mitigating the risk of diseases. The South Korea Personalized Medicine Market segmentation showcases an industry that is poised for robust growth due to burgeoning consumer demand for personalized approaches aligned with modern healthcare paradigms. The government of South Korea is also incentivizing personalized medicine initiatives to enhance the overall healthcare landscape, presenting further opportunities for stakeholders within these segments. Overall, the diverse array of product categories within the South Korea Personalized Medicine Market illustrates its potential to transform traditional healthcare practices into a more individualized approach, thereby contributing to better health outcomes and efficiency in treatment modalities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Personalized Medicine Market Application Outlook Insights** The South Korea Personalized Medicine Market, particularly in the Application Outlook segment, is experiencing substantial growth, reflecting a wider global trend towards tailored healthcare solutions. Oncology plays a crucial role within this market, as it addresses the rising incidence of cancer, necessitating distinctly targeted therapies that enhance treatment efficacy and minimize side effects. In addition to oncology, the Central Nervous System (CNS) applications are gaining traction, addressing disorders like Alzheimer's and Parkinson's disease through personalized approaches that adapt to the individual’s specific genetic makeup. Immunology is another significant area, with personalized treatments offering innovative solutions for autoimmune diseases and allergies, thereby improving patient outcomes. The respiratory segment also holds prominence, particularly with advancements in treating chronic respiratory conditions such as asthma and COPD, highlighting the integration of genetic insights in managing these diseases. Furthermore, 'Others' encompasses a variety of emerging applications, emphasizing the breadth of personalized medicine's impact in various healthcare facets. Overall, the South Korea Personalized Medicine Market segmentation reflects a comprehensive approach to healthcare, driven by advancements in biotechnology, increasing patient demand for customized therapies, and supportive government initiatives promoting personalized health solutions. **Personalized Medicine Market End-User Outlook Insights** The South Korea Personalized Medicine Market encompasses a diverse End-User Outlook, which includes Hospitals, Diagnostic Centers, Research Academic Institutes, and Others, playing a pivotal role in the market landscape. Hospitals form a critical backbone, as they are increasingly utilizing personalized medicine approaches to enhance patient care and treatment outcomes, driven by the rising prevalence of chronic diseases in the region. Diagnostic Centers are gaining traction as they provide essential testing services that facilitate tailored therapies, thus reflecting the growing demand for precision diagnostics in the healthcare system. Research Academic Institutes contribute significantly to the innovation and development of personalized medicine, focusing on molecular biology and genetics, which is essential for advancing treatment methodologies. The Others category, encompassing various healthcare facilities and organizations, is also vital, as it supports the integration of personalized medicine into broader healthcare practices. Collectively, these segments form the backbone of the South Korea Personalized Medicine Market, addressing unique healthcare needs and responding to the shift toward more individualized patient care. The ongoing advancements in technology and growing investments in healthcare are expected to drive further growth across these segments, highlighting the importance of targeted approaches in transforming healthcare delivery in South Korea. **South Korea Personalized Medicine Market Key Players and Competitive Insights** The South Korea Personalized Medicine Market is a rapidly evolving sector characterized by innovation and a focus on tailored healthcare solutions aimed at individual patient needs. With advancements in genomics, diagnostics, and biotechnology, the market is witnessing an increase in the integration of personalized treatment approaches across various medical disciplines. The competitive landscape is shaped by a mix of established healthcare giants and emerging companies that capitalize on state-of-the-art technology and research capabilities. The incorporation of precision medicine into clinical practices is positioning stakeholders favorably against traditional treatment methodologies, enabling them to deliver higher efficacy and improved patient outcomes. As stakeholders across the pharmaceutical and healthcare industries adapt to the growing demand for customization in care, the market is expected to undergo significant transformation and expansion over the coming years. Roche stands out prominently in the South Korea Personalized Medicine Market, leveraging its extensive research capabilities and robust product portfolio. The company has established a strong presence in the field, particularly in diagnostics and therapeutics that align with personalized healthcare objectives. Roche’s strengths lie in its deep commitment to research and development, enabling it to lead in the development of innovative solutions tailored to patient-specific needs. The company is recognized for its contributions to oncology and molecular diagnostics, enhancing its position as a front-runner in the rapidly evolving personalized medicine landscape. By actively engaging in collaborations with local healthcare and research institutions, Roche is fueling the advancement of personalized treatments that align with the evolving expectations of the South Korean healthcare system. Samsung Medical Center, a prominent healthcare institution in South Korea, plays a critical role in the personalized medicine landscape, emphasizing precision care through advanced diagnostics and treatment options. The center offers a range of services including tailored cancer therapies and genetic testing, underscoring its commitment to personalized healthcare. Samsung Medical Center's strengths are highlighted by its cutting-edge facilities and research initiatives that push the boundaries of conventional medicine. The institution is known for its collaborations with global partners in pursuing innovations that enhance treatment protocols for chronic diseases. Additionally, the healthcare provider is engaged in strategic partnerships and acquisitions aimed at expanding its capabilities in the field of personalized medicine, positioning itself as a leader in comprehensive patient care. With a reputation for excellence in medical services, Samsung Medical Center continues to influence the direction of personalized medicine in South Korea, reflecting the growing importance of patient-centric approaches in modern healthcare. **Key Companies in the South Korea Personalized Medicine Market Include** - Roche - Samsung Medical Center - Hanmi Pharmaceutical - Amgen - Novartis - Pfizer - Genexine - Seegene - SillaJen - Medtronic - AbbVie - LG Chem - Celltrion - SK Biopharmaceuticals - Korean Biobank **South Korea Personalized Medicine****Market****Developments** In recent months, the South Korea Personalized Medicine Market has experienced notable advancements and activities. Samsung Medical Center continues to lead in genomic research and patient-specific customized treatment plans, while Genexine is pushing forward with its innovative cancer therapies focused on personalized approaches. Major pharmaceutical companies like Roche and Novartis are investing in collaborations aimed at enhancing drug delivery systems that cater to genetic variations among patients, thereby reinforcing their foothold in the market. In August 2023, Celltrion announced a partnership with AbbVie aimed at co-developing personalized therapy options, highlighting the trend toward strategic alliances to leverage expertise. Furthermore, the growing demand for precision medicine has been reflected in the market valuation, which has seen significant growth driven by advanced genomic technologies and diagnostic tools offered by companies like Seegene and SK Biopharmaceuticals. Notably, in May 2022, Hanmi Pharmaceutical successfully launched a new personalized treatment protocol, enhancing its market position and catering to the unique needs of patients in South Korea. The Korean government's strong focus on biotechnology innovation and research is significantly fueling the growth of the personalized medicine segment, as evidenced by investment incentives and increased support for biopharmaceutical research initiatives. **South Korea Personalized Medicine Market Segmentation Insights** **Personalized Medicine Market****Product****Outlook** - Personalized Medicine Diagnostics - Personalized Medicine Therapeutics - Personalized Medical Care - Personalized Nutrition and Wellness **Personalized Medicine Market****Application****Outlook** - Oncology - CNS - Immunology - Respiratory - Others **Personalized Medicine Market****End-User****Outlook** - Hospitals - Diagnostic Centers - Research Academic Institutes - Others -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Rising Incidence of Chronic Diseases The increasing prevalence of chronic diseases in South Korea is a pivotal driver for the personalized medicine market. As the population ages, conditions such as diabetes, cancer, and cardiovascular diseases are becoming more common. This trend necessitates tailored treatment approaches that can effectively address individual patient needs. According to recent health statistics, chronic diseases account for approximately 80% of healthcare costs in the country. Consequently, healthcare providers are increasingly adopting personalized medicine strategies to enhance treatment efficacy and improve patient outcomes. The personalized medicine market is thus positioned to grow as healthcare systems seek innovative solutions to manage these complex health challenges. ### Advancements in Diagnostic Technologies Innovations in diagnostic technologies are significantly influencing the personalized medicine market. The development of advanced genomic sequencing and biomarker identification techniques allows for more precise patient stratification and treatment customization. In South Korea, the market for diagnostic tools is projected to reach $1.5 billion by 2026, reflecting a robust demand for technologies that facilitate personalized treatment plans. These advancements enable healthcare professionals to identify the most effective therapies based on individual genetic profiles, thereby improving treatment success rates. As diagnostic capabilities continue to evolve, the personalized medicine market is likely to expand, driven by the need for more accurate and efficient healthcare solutions. ### Collaboration Between Academia and Industry The collaboration between academic institutions and the pharmaceutical industry is a significant driver of the personalized medicine market. In South Korea, partnerships are being formed to leverage academic research in genomics and biotechnology for the development of new therapies. These collaborations often result in the translation of scientific discoveries into practical applications, enhancing the efficacy of personalized treatments. With an estimated 30% of new drug approvals in recent years stemming from such partnerships, the impact on the personalized medicine market is profound. This synergy not only accelerates the pace of innovation but also ensures that emerging therapies are grounded in robust scientific evidence, ultimately benefiting patients. ### Regulatory Support for Innovative Therapies Regulatory frameworks in South Korea are increasingly supportive of innovative therapies, which is beneficial for the personalized medicine market. The Ministry of Food and Drug Safety (MFDS) has implemented streamlined approval processes for personalized treatments, facilitating quicker access to novel therapies for patients. This regulatory environment encourages pharmaceutical companies to invest in the development of personalized medicine solutions. As a result, the market is likely to experience accelerated growth, with more products entering the market. The proactive stance of regulatory bodies not only enhances patient access to cutting-edge treatments but also stimulates competition among manufacturers, further driving innovation in the personalized medicine market. ### Increased Investment in Research and Development Investment in research and development (R&D) is a crucial driver for the personalized medicine market. South Korea's government and private sector are channeling substantial resources into R&D initiatives aimed at discovering new therapies and improving existing ones. In 2025, R&D spending in the biopharmaceutical sector is expected to exceed $3 billion, highlighting the commitment to advancing personalized medicine. This influx of funding supports the exploration of novel treatment modalities and the integration of cutting-edge technologies, such as artificial intelligence and machine learning, into healthcare practices. As R&D efforts intensify, the personalized medicine market is poised for significant growth, fostering innovation and enhancing patient care. ## Future Outlook The [Personalized Medicine Market](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) in South Korea is projected to grow at a 6.42% CAGR from 2025 to 2035, driven by advancements in genomics, technology integration, and increasing healthcare demand. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Investment in biobanking for personalized drug development and research. By 2035, the personalized medicine market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Personalized Medicine Diagnostics (Largest) vs. Personalized Medicine Therapeutics (Fastest-Growing) In the South Korea personalized medicine market, Personalized Medicine Diagnostics currently holds the largest share among the different segments, significantly contributing to the overall growth of the market. This segment's dominance can be attributed to the increasing demand for precision diagnostics and the rise in chronic disease prevalence, making it essential for tailored treatment plans. On the other hand, Personalized Medicine Therapeutics is emerging as the fastest-growing segment, driven by advancements in drug development and a focus on individualized treatment protocols. Factors such as increased investment in R&D, favorable government policies, and a growing emphasis on patient-centric approaches are fueling this segment's rapid expansion, positioning it as a key player in the personalized medicine landscape. Diagnostics (Dominant) vs. Therapeutics (Emerging) Personalized Medicine Diagnostics serves as the dominant force in the South Korea personalized medicine market, characterized by its robust technology for disease detection and monitoring tailored to individual patient profiles. This segment's effectiveness in improving patient outcomes and its integration into standard healthcare practices underscore its critical role. Conversely, Personalized Medicine Therapeutics represents an emerging segment that focuses on developing customized treatment regimens based on genetic makeup and personal health data. This segment shows significant promise due to ongoing innovations in drug therapies and a rising number of personalized treatment options, appealing to healthcare providers and patients alike as they seek more effective and tailored solutions. ### By Application: Oncology (Largest) vs. CNS (Fastest-Growing) In the South Korea personalized medicine market, Oncology currently holds the largest share, dominating the application segment due to its advanced research and development initiatives. Following close behind, the CNS area has emerged as a significant player, fueled by increasing attention to neurological disorders. The distribution of market shares reflects the growing demand for targeted therapies in various chronic diseases, solidifying Oncology's leading position while highlighting the increasing awareness of CNS conditions. Growth trends in the segment show a dynamic shift toward the CNS application, which has become the fastest-growing area in recent years. This growth is driven by advancements in genomics and biologics, allowing for personalized approaches to treatment. The demand for innovative therapies that cater to specific patient needs in both Oncology and CNS applications is set to propel the market further, making it crucial for stakeholders to align their strategies accordingly. Oncology (Dominant) vs. CNS (Emerging) Oncology has established itself as the dominant segment in the South Korea personalized medicine market, characterized by robust research initiatives and investment in cancer therapies. This dominance is attributed to the high prevalence of cancer and an increased focus on personalized treatment approaches. In contrast, the CNS segment is rapidly emerging, reflecting a growing concern for neurological health and mental illnesses, which are gaining recognition as crucial areas of public health. The swift developments in biomarkers and targeted therapies personalized for CNS disorders promise a transformative impact, making it an area to watch for future growth. The ongoing collaboration between biotechnology firms and research institutions is expected to amplify innovations across both segments. ### By End-User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing) The South Korea personalized medicine market exhibits a diverse distribution among key end-user segments. Hospitals hold the largest market share, driven by an increasing demand for tailored treatment options that enhance patient outcomes. As healthcare institutions continue to adopt personalized medicine principles, they significantly influence the market landscape, with robust infrastructure and investment in advanced technologies supporting their position. Diagnostic centers are emerging as the fastest-growing segment within the market. This growth is driven by the rise in genetic testing and biomarker analysis, which empowers diagnostic facilities to provide precise and individual treatment recommendations. The increasing emphasis on early diagnosis and preventive healthcare is further propelling the development of this segment, positioning diagnostic centers as critical players in the personalized medicine domain. Hospitals: Dominant vs. Diagnostic Centers: Emerging Hospitals are recognized as the dominant force in the South Korea personalized medicine market, offering comprehensive services that integrate cutting-edge technologies for customized patient care. Their established infrastructure, combined with experienced medical professionals, enables the effective implementation of personalized treatment strategies. On the other hand, diagnostic centers are considered an emerging segment, rapidly expanding due to advancements in molecular diagnostics and personalized testing. These centers are essential for the accurate identification of individual patient needs, thus directly contributing to the rise of personalized medicine. The collaboration between hospitals and diagnostic centers enhances the overall quality and efficiency of patient management, driving innovation and progress in the market. ## Competitive Benchmarking The personalized medicine market in South Korea is characterized by a dynamic competitive landscape, driven by rapid advancements in genomics, biotechnology, and data analytics. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are at the forefront, leveraging their innovative capabilities to enhance patient outcomes. Roche (CH) focuses on integrating diagnostics with therapeutics, thereby creating a seamless approach to personalized treatment. Meanwhile, Thermo Fisher Scientific (US) emphasizes its commitment to expanding its product portfolio through strategic partnerships and acquisitions, which enhances its market presence. Illumina (US) continues to lead in genomic sequencing technologies, positioning itself as a critical player in the development of personalized therapies. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players exerting substantial influence. This fragmentation allows for a diverse range of offerings, yet the presence of dominant firms like Roche (CH) and Illumina (US) suggests a competitive hierarchy that shapes market dynamics. In October Roche (CH) announced a collaboration with a leading South Korean biotech firm to develop a novel biomarker for cancer treatment. This strategic partnership is likely to enhance Roche's capabilities in personalized oncology, aligning with its goal of integrating diagnostics and therapeutics. Such collaborations may significantly accelerate the development of targeted therapies, thereby reinforcing Roche's competitive edge in the market. In September Thermo Fisher Scientific (US) launched a new suite of genomic analysis tools tailored for the South Korean market. This introduction not only reflects the company's commitment to innovation but also indicates a strategic move to capture a larger share of the growing demand for personalized medicine solutions. By localizing its product offerings, Thermo Fisher Scientific (US) is likely to strengthen its market position and enhance customer engagement. In August Illumina (US) expanded its partnership with local research institutions to enhance genomic research capabilities in South Korea. This initiative underscores Illumina's strategy to foster innovation through collaboration, which may lead to breakthroughs in personalized medicine applications. By investing in local research, Illumina (US) is positioning itself as a leader in the region, potentially influencing the future direction of personalized therapies. As of November current trends in the personalized medicine market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, emphasizing the importance of agility and responsiveness in a rapidly changing environment. ## Recent News & Developments In recent months, the South Korea Personalized Medicine Market has experienced notable advancements and activities. Samsung Medical Center continues to lead in genomic research and patient-specific customized treatment plans, while Genexine is pushing forward with its innovative cancer therapies focused on personalized approaches. Major pharmaceutical companies like Roche and Novartis are investing in collaborations aimed at enhancing drug delivery systems that cater to genetic variations among patients, thereby reinforcing their foothold in the market. In August 2023, Celltrion announced a partnership with AbbVie aimed at co-developing personalized therapy options, highlighting the trend toward strategic alliances to leverage expertise. Furthermore, the growing demand for precision medicine has been reflected in the market valuation, which has seen significant growth driven by advanced genomic technologies and diagnostic tools offered by companies like Seegene and SK Biopharmaceuticals. Notably, in May 2022, Hanmi Pharmaceutical successfully launched a new personalized treatment protocol, enhancing its market position and catering to the unique needs of patients in South Korea. The Korean government's strong focus on biotechnology innovation and research is significantly fueling the growth of the personalized medicine segment, as evidenced by investment incentives and increased support for biopharmaceutical research initiatives. ## Report Scope | MARKET SIZE 2024 | 14.92(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 15.88(USD Billion) | | MARKET SIZE 2035 | 29.57(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck & Co. (US), Amgen (US) | | Segments Covered | Product, Application, End-User | | Key Market Opportunities | Integration of artificial intelligence in personalized medicine enhances treatment precision and patient outcomes. | | Key Market Dynamics | Rising demand for tailored therapies drives innovation and competition in South Korea's personalized medicine market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation of personalized medicine in South Korea in 2024?** A: The market valuation of personalized medicine in South Korea was $14.92 Billion in 2024. **Q: What is the projected market valuation for personalized medicine in South Korea by 2035?** A: The projected market valuation for personalized medicine in South Korea is $29.57 Billion by 2035. **Q: What is the expected CAGR for the South Korea personalized medicine market during the forecast period 2025 - 2035?** A: The expected CAGR for the South Korea personalized medicine market during the forecast period 2025 - 2035 is 6.42%. **Q: Which segment of personalized medicine diagnostics had the highest valuation in 2024?** A: In 2024, the personalized medicine diagnostics segment had a valuation of $3.74 Billion. **Q: What is the projected valuation for personalized medicine therapeutics by 2035?** A: The projected valuation for personalized medicine therapeutics is $11.92 Billion by 2035. **Q: Which application segment is expected to grow the most in the South Korea personalized medicine market?** A: The oncology application segment is expected to grow the most, with a projected valuation of $11.79 Billion by 2035. **Q: What was the valuation of personalized medical care in 2024?** A: The valuation of personalized medical care in 2024 was $2.98 Billion. **Q: Which end-user segment had the highest valuation in 2024?** A: In 2024, the hospitals end-user segment had the highest valuation at $5.96 Billion. **Q: What is the projected valuation for personalized nutrition and wellness by 2035?** A: The projected valuation for personalized nutrition and wellness is $4.48 Billion by 2035. **Q: Who are the key players in the South Korea personalized medicine market?** A: Key players in the South Korea personalized medicine market include Roche, Thermo Fisher Scientific, Illumina, Novartis, GSK, Bristol-Myers Squibb, Pfizer, Merck & Co., and Amgen. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-personalized-medicine-market-45309*